The GLP-1 companion-supplement market was valued at roughly $735 million in the US in 2025 and is projected to keep growing at a double-digit annual rate through the early 2030s
[12] [13] These medications have demonstrated benefits in reducing HbA1c, promoting weight loss, andfor some agentsreducing cardiovascular risk
Neuroprotective Effects Emerging research suggests GLP-1 medications may have neuroprotective properties, potentially benefiting cognitive function and reducing the risk of neurodegenerative diseases like Alzheimers
Nooms Program By combining individualized titration protocols with daily, appbased behavior change, we aim to support sustainable weight loss with a fraction of the drug exposure and a fraction of the side effects
Eligibility and medication decisions are made by external licensed clinicians after intake review
Research also suggests GLP-1 users are over two times more likely to experience GERD than those not taking the medication, and their risk of developing gallstones increases by nearly 50%